ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
7 announcements with these filters
Viyash Scientific delivered strong Q1 FY27 results with 19.5% revenue growth and significant margin expansion. Integration is complete, and the company is now virtually debt-free, pivoting toward oncology and companion animal health.
Viyash reports a robust Q1FY27 with 20% revenue growth and significantly expanded EBITDA margins at 21.6%. The company is essentially net-debt free following successful integration and is pivoting toward high-potent oncology products.
Viyash Scientific reported strong Q1 FY27 results with 19.5% YoY revenue growth and 59.2% EBITDA growth, driven by integration success and operational leverage.
Viyash Scientific targets a $1Bn revenue platform by 2032 through the merger of Sequent and Viyash Life Sciences, focusing on animal and human health.
Viyash reports a transformative Q4 FY26 with EBITDA surpassing ₹200cr. Revenue rose 19.1% YoY to ₹920cr, driven by integration synergies and a shift toward high-potent human and animal health products.
Viyash delivered a breakout FY26 with Q4 EBITDA crossing 200cr, marking a successful business integration.
Viyash Q4 FY26 revenue reached ₹9,200 Mn with 21.7% EBITDA margins. Management highlights successful integration and a deleveraged balance sheet.